Key Highlights

  • TriSalus Life Sciences (NASDAQ:TLSI) finished Tuesday, November 10, 2026 at USD 2.46, a 23.76% decline from a calculated previous close of USD 3.23, which placed it near the bottom of a published screener snapshot covering 4,625 names.
  • The third quarter 2026 release, dated November 10, 2026, reported Revenue of USD 12.9 million, an 11.3% rise from USD 11.6 million, and moved 2026 revenue guidance to between USD 46 million and USD 48 million.
  • Trading reached 623.61K shares, a relative Volume of 4.11 and roughly USD 1.53 million in value at the close (calculated), while the snapshot lists a Market Value of USD 151.17 million.
  • Cash stood at USD 41.1 million on September 30, 2026, set against a quarterly net loss of USD 8.9 million, or USD 0.15 per share, compared with a loss of USD 0.96 per share one year before.

Why TriSalus Life Sciences Slid on November 10 (-23.76%)

TriSalus Life Sciences, a US-listed medical technology name, closed its regular session at USD 2.46, lower by 23.76%. Simple arithmetic points to a calculated previous close of USD 3.23 on Monday, November 9, 2026, a drop near USD 0.77 per share. With 623.61K shares changing hands at a relative volume of 4.11, the implied average is about 151.7K shares (calculated), about four times the usual pace. The snapshot lists trailing diluted EPS of USD -1.30, EPS growth of -9.89%, no P/E and a Dividend Yield of 0.00%. The company filed its third quarter 2026 Earnings release as an 8-K dated November 10, 2026. The release timing relative to trading hours is unconfirmed, so tying it to the decline is an inference and not a stated cause.

The Rationale: Third Quarter Results and Revised Guidance

The one identified catalyst is the results release. Revenue for the third quarter of 2026 came to USD 12.9 million, up 11.3%, and gross Margin widened to 86.2% from 83.5%. The net loss was USD 8.9 million, or USD 0.15 per share, whereas the year-earlier figure attributable to common stockholders was USD 41.3 million, or USD 0.96 per share, which included about USD 30.5 million tied to a preferred stock conversion. Adjusted EBITDA loss narrowed to USD 4.7 million from USD 5.4 million. Guidance for full-year 2026 revenue now sits at USD 46 million to USD 48 million, roughly 2% to 6% growth. Nine-month revenue of USD 33.2 million implies the fourth quarter has to produce USD 12.8 million to USD 14.8 million to land inside that range (calculated). In general terms, a changed outlook can reset expectations quickly, yet that is a general mechanism and not a confirmed cause.

Valuation, Liquidity and Risks for TriSalus Life Sciences

A market value of USD 151.17 million lines up with 61,659,370 shares outstanding on September 30, 2026, which works out to about USD 151.7 million at USD 2.46 (calculated), so the numbers reconcile. Measured against the USD 47 million guidance midpoint, that equals about 3.2 times sales (calculated). The cash balance of USD 41.1 million follows a USD 46.0 million gross Equity offering in the first quarter of 2026. Sales and Marketing spending climbed to USD 10.7 million from USD 6.8 million, which keeps the loss sizeable. Specific risks include a further equity raise and dilution, delivery against a back-loaded fourth quarter target, and a 23.76% price move in one session. Liquidity is modest, so spreads can widen. Nothing here indicates the move will continue.

Where Things Stand

TriSalus Life Sciences (NASDAQ:TLSI) dropped 23.76% to USD 2.46 on November 10, 2026, the day it released third quarter results and a new 2026 revenue range of USD 46 million to USD 48 million. How the release lined up with the session is unconfirmed, so the connection is an inference.